

a
PBMC
48.3
CD4
CD25
b
CD4+ cells
1.7
92.2
3.5
2.5
Foxp3
CD25
4.2
8.6
0.9
86.1
CD127
3.5
31.8
1.7
62.9
CD49d

Fig. 1



a
CD4+ cells
88.5
2.4
2.8
CD49d
CD127
CD49d+CD127-
17.4
CD49d-CD127-
83.9
CD127+
3.6
Foxp3
CD25

FIG. 2



b
CD127
CD49d
CD4+ cells
37.5
38.6
13.3
10.4
FACS-sorted
CD4+ populations
CD49d-
CD127-
3.7
3.2
90.0
2.9
CD49d+
CD127-
1.1
1.7
10.6
96.5
c
% Inhibition
0
10
20
30
40
50
60
70
80
CD49d-
CD127-
CD49d+
CD127-

Fig. 2



a
CD4+ cells
Prior to depletion
CD49d/CD127-depleted
(Treg cells)
CD127
CD49d
Foxp3
CD25
44.1
47.9
3.7
4.1
11.3
16.0
2.0
70.5
3.7
0.3
95.9
0.0
92.2
2.0
1.8
3.8
b
CD4+ cells (non-stimulated)
0.2
CD4+ cells
44.7
CD4+ cells & Treg cells
14.0
SSC
CFDA

Fig. 3





PBMC (prior to depletion)
PBMC (after depletion)
one-step-depletion
CD127/CD49d-depletion only
CD127/CD49d-depletion & CD4-isolation
a
b
CD127
CD49d
Foxp3
CD25
16.2
2.5
38.7
42.3
4.6
91.3
1.4
2.6
2.0
96.7
0.0
1.1
11.8
11.1
64.3
12.6
15.5
4.0
31.2
49.1
2.1
85.8
2.4
9.4
0.5
97.7
0.7
1.0
14.1
17.3
76.2
2.2

Fig. 4

a



b



	Clinical Symptoms	Death
CD25- PBMC	4/6	2/6
CD25- PBMC & Treg	0/6	0/6

Fig. 5



total CD4+ cells
CD49d
51.0
2.0
46.6
0.2
IL-17
37.3
20.6
41.1
0.8
IFN-γ
Foxp3+CD4+ cells
19.1
34.2
65.6
20.4
30.9
69.0
b
CD25high49d+
CD25highCD49d-
6.9
0.1
92.0
0.8
0.3
0.0
99.4
0.1

Fig. 6



CD4+ cells
before CD49d depletion
after CD49d depletion
7.0
33.2
Foxp3
CD25
8.2
34.6
CD49d
Foxp3

Fig. 7



CD4+ cells
CD127+
CD49d-CD127-
CD49d+CD127-
IFNγ
IL-17
40.9
0.7
56.0
2.2
2.2
0.0
96.8
1.5
20.5
0.4
75.5
3.2

Fig. 8